findmyKOL
Clinical trialNCT05522894UnknownPhase 2Interventional

AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC

SponsorChinese Academy of Medical SciencesEnrollment80Locally Advanced Esophageal Squamous Cell CarcinomaMetastatic Esophageal Squamous Cell CarcinomaUnresectable Esophageal Squamous Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Jing Huang, M.D.

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Oct 2022
Primary completion
1 Apr 2024
Completion
1 Oct 2024
Last update posted
31 Aug 2022
Registered enrollment
80
Registry id
NCT05522894

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.